Table 1.
Immunogenicity Response (GMTs) of Study Groups 4 Weeks After the Last Dose of RV5
| Anti-rotavirus Titer | GMTs (95% CI) | |||
|---|---|---|---|---|
| Group A (Standard Schedule) (N = 27) | Group B (Alternative Schedule) (N = 28) | Subgroup B-1 (14- to 20-day-olds) (N = 9) | Subgroup B-2 (21- to 41-day-olds) (N = 19) |
|
| Serotype G1 | 188 (117.9–299.7) | 184.5 (117–290.8) | 245.3 (90.8–662.4) | 161.2 (93.7–277.2) |
| Serotype G2 | 38.7 (25–59.9) | 33.1 (20.7–52.9) | 77.6 (36.9–163.1) | 22.1 (12.9–37.8) |
| Serotype G3 | 42.1 (27.5–64.6) | 27.3 (17.3–43.2) | 50 (19.2–130.2) | 20.5 (12.2–34.3) |
| Serotype G4 | 144.6 (105.1–198.8)a | 66.5 (50.7–87.1)a | 83.9 (53.8–130.7) | 59.6 (41.8–84.9)a |
| Serotype P1 | 114.7 (77.51–169.6) | 136.5 (84.91–219.3) | 298.0 (138.9–639.2) | 94.3 (53.8–165.3) |
| Rotavirus IgA | 318.3 (179.7–563.8) | 183.7 (93.37–361.6) | 173.9 (42.5–711.8) | 188.6 (81–439.2) |
Abbreviations: CI, confidence interval; GMT, geometric mean titer; IgA, immunoglobulin A; RV5, pentavalent rotavirus vaccine.
aSignificant differences (no overlap of 95% CIs) between groups A and B and between group A and subgroup B-2 (21–41 days old).